How soon after amputation can I try ketamine?

Some evidence supports early perioperative use of ketamine for prevention, though chronic phantom limb pain is the better-established indication. If you are within the surgical window, coordinate with your surgical and pain teams first. For established phantom limb pain weeks, months, or years after amputation, the evidence base is stronger and treatment can be initiated whenever you and your prescribing clinician agree it is reasonable to try.

Will ketamine work for stump pain too?

Stump pain (residual limb pain) has overlapping nociceptive and neuropathic components. The neuropathic, centrally driven component tends to respond more reliably to ketamine, while purely mechanical stump pain from a poor prosthetic fit or neuroma usually does not. A partial response is realistic, and we always recommend coordinating with your prosthetist and pain physician to address mechanical contributors alongside any infusion course.

Is one infusion enough?

Single infusions can produce meaningful pain reductions, as Eichenberger 2008 demonstrated, but durability is the issue. Most pain-clinic protocols use a multi-infusion induction series followed by periodic boosters. The optimal schedule is still being defined in the literature and varies by patient. We work with your prescribing physician to design a course that matches your response and your goals.

How does ketamine compare to a spinal cord stimulator?

They are different mechanisms with very different invasiveness profiles. A spinal cord stimulator is an implanted device that requires a surgical trial and permanent implantation. Ketamine is a non-implanted, reversible pharmacologic trial. Many pain physicians consider a ketamine course before implantation, both as a less-invasive option and to gauge whether central sensitization is a meaningful driver of the pain. Some patients use both.

Can I keep my opioids during a ketamine course?

Generally yes. Ketamine sometimes lets patients reduce their opioid dose because it addresses a different mechanism, but we do not stop or change opioid prescriptions unilaterally. We coordinate with your prescribing physician throughout. Marla Peterson, CRNA, oversees every infusion with anesthesia-level monitoring, and any tapering decisions stay with the clinician who manages your overall pain regimen.

Ketamine for phantom limb pain: one of the better-evidenced uses

What phantom limb pain actually is

Phantom limb pain is the sensation of pain that appears to come from a limb that is no longer there. It is not the same as residual limb pain (sometimes called stump pain), which originates in the remaining tissue, and it is not the same as a phantom sensation that lacks a painful quality. Patients describe phantom limb pain as burning, electric, cramping, stabbing, or as a sense that the missing limb is contorted or trapped in an unnatural position.

The condition is common after amputation. Estimates from the International Association for the Study of Pain and other groups place the prevalence at roughly 60 to 80 percent of amputees in the months following surgery, with a substantial fraction continuing to experience pain for years. The cohort is broad: traumatic limb loss, surgical amputation for vascular disease or cancer, and combat-related injuries all produce phantom limb pain in similar proportions.

Standard treatments include gabapentinoids, tricyclic antidepressants, mirror therapy, transcutaneous electrical nerve stimulation, opioids in some refractory cases, and increasingly, peripheral nerve interventions and spinal cord stimulators. Each helps a subset of patients. None reliably eliminates pain that has become entrenched, and most have a meaningful side-effect burden when used long term.

Why NMDA antagonists make biological sense here

The mechanism that drives chronic phantom limb pain has come into sharper focus over the last two decades. After amputation, the loss of normal sensory input from the limb prompts reorganization in the spinal cord and somatosensory cortex. This reorganization is not benign. It often involves increased excitability in pain-processing circuits, a phenomenon researchers describe as central sensitization. Glutamate signaling at the NMDA receptor sits at the heart of that process.

This is the same mechanism that has been implicated in complex regional pain syndrome, neuropathic pain after nerve injury, and the wind-up phenomenon documented in spinal cord physiology. The framing parallels what we describe in our article on ketamine for CRPS: when the central nervous system has effectively learned to produce pain in the absence of ongoing tissue damage, treatments that act downstream of that learning tend to underperform. Treatments that act on the learning machinery itself are more interesting.

Ketamine is the most potent and best-characterized NMDA receptor antagonist available in clinical medicine. It binds inside the channel of the receptor and physically blocks glutamate-mediated excitatory signaling. In the context of phantom limb pain, that pharmacology gives it a plausible reason to work where calcitonin, peripherally acting analgesics, and many oral agents have not. Ketamine is FDA-approved as an anesthetic; its use for phantom limb pain and other chronic pain conditions is off-label.

The Eichenberger 2008 trial in detail

The most-cited piece of evidence for ketamine in phantom limb pain remains the 2008 randomized, double-blind, placebo-controlled crossover trial by Eichenberger and colleagues, published in Anesthesia & Analgesia (volume 106, pages 1265–1273). The investigators studied chronic phantom limb pain in adults who had been struggling with pain for months to years after amputation. Each subject received IV ketamine 0.4 mg/kg, IV calcitonin, the combination, and placebo on separate occasions, in randomized order, with appropriate washout periods.

The result was clear. IV ketamine produced significant reductions in spontaneous phantom limb pain and shifted sensory thresholds in a way consistent with reduced central sensitization. Calcitonin, which had been a popular candidate at the time, did not separate from placebo. The combination of ketamine plus calcitonin was not superior to ketamine alone, which the authors interpreted as further evidence that the analgesic action was specifically NMDA-mediated rather than additive across mechanisms.

This trial is small by modern standards, but its design is the part that matters. Crossover comparisons with placebo and an active comparator, double blinding, and objective sensory testing all raise the quality of the signal. Twenty years on, it still anchors most reviews of pharmacologic options for refractory phantom limb pain.

IV ketamine 0.4 mg/kg reduced phantom limb pain and altered sensory thresholds; calcitonin did not. The combination was not superior to ketamine alone—implicating NMDA-mediated central sensitization as the operative mechanism. — Eichenberger et al., Anesthesia & Analgesia, 2008

Beyond Eichenberger: oral ketamine, repeat infusions, and case series

The literature did not stop in 2008. A 2010 paper by Shanthanna and colleagues in the Indian Journal of Anaesthesia described early ketamine in the post-amputation period for phantom-limb pain, contributing to the now-active research line on whether NMDA blockade around the time of surgery can actually prevent the chronification of phantom pain rather than only treating it after the fact. The evidence for prevention is still mixed and weaker than the evidence for treatment of established pain.

A 2015 case report in the Indian Journal of Anaesthesia described oral ketamine as a treatment option for refractory phantom limb pain when IV access or repeat infusion was impractical. Oral ketamine has lower bioavailability and a different pharmacokinetic profile than IV, and clinicians generally consider it a complement to IV induction rather than a substitute, but the report illustrates that the analgesic signal carries across routes. We discuss the trade-offs in detail in our piece on oral vs. IV ketamine.

Smaller case series and observational reports have continued to appear in the pain literature, generally pointing in the same direction: a meaningful subset of patients with chronic phantom limb pain experience clinically important reductions with IV ketamine, and durability tends to be the limiting factor rather than initial response. For a broader view of the chronic-pain evidence base, our overview of ketamine for chronic pain walks through the wider data set.

Where this fits next to CRPS, neuropathic pain, and fibromyalgia

Phantom limb pain sits inside a family of central-sensitization-driven conditions for which ketamine has accumulated evidence over the last twenty years. CRPS shares the same core mechanism and has arguably the strongest randomized evidence base for IV ketamine. Neuropathic pain from nerve injury or compression overlaps mechanistically and tends to respond in a similar pattern—some patients have substantial benefit, some have partial benefit, and some do not respond.

Compared to its role in chronic pain overall, phantom limb pain is one of the indications where the biological argument and the clinical evidence line up unusually well. That does not guarantee a response in any individual case, but it does mean a trial of ketamine is a reasonable step earlier in the treatment ladder than it might be for less mechanistically aligned conditions. Studies indicate that patients who have already failed gabapentinoids, tricyclics, and mirror therapy are the population in whom ketamine is most often considered today.

Who's a candidate and what to expect

The strongest candidates we see for ketamine in phantom limb pain tend to share a few features:

Established phantom limb pain that has not responded adequately to standard care. Gabapentinoids, tricyclics, mirror therapy, and TENS should generally have been tried, with input from a pain physician.
A pain pattern consistent with central sensitization. Burning, electric, or cramping pain referred to the missing limb, often with allodynia at the residual limb or contralateral limb, fits the NMDA-driven pattern most directly.
Coordination with a pain physician and, when relevant, a prosthetist. Mechanical contributors at the residual limb need their own management; ketamine does not fix a poorly fitting socket.
Stable medical status appropriate for an outpatient infusion—reasonable cardiovascular control, no untreated psychotic illness, no contraindicating medication interactions.

At Music City Ketamine, the process begins with a thorough consultation. We review the diagnosis, treatment history, current medications, and pain pattern to decide whether a course is appropriate. Chronic-pain protocols differ in dose and duration from mental-health protocols, and the plan is individualized. Marla Peterson, CRNA, oversees every infusion with anesthesia-level monitoring—continuous pulse oximetry, blood pressure, and heart rate—using the same standard described in our ketamine vs. opioids overview. The clinic environment is private and quiet, with comfortable recliners and our therapy dogs, Walter White and Wilma, on hand for patients who want them.

You will need a driver. Most patients resume normal activity the next day. Sessions at Music City Ketamine are $475 each, and as with most off-label pain uses, insurance typically does not reimburse. We are upfront about that. For a closer look at how clinic infusions compare to other ketamine formats, our piece on IV vs. at-home ketamine walks through the differences.

Coordinating with your pain physician and prosthetist

We do not replace a pain physician—we work alongside one. If you do not already have a pain physician managing your phantom limb pain, we will encourage you to establish that relationship, because durable results almost always come from a coordinated plan rather than from a single treatment in isolation. The prosthetist matters too; mechanical issues at the residual limb can mimic or amplify central pain, and a poorly fitting prosthetic will undermine any pharmacologic gain.

Decisions about gabapentinoids, opioids, antidepressants, or other medications stay with your prescribing clinician. We do not stop or change those medications unilaterally. If a ketamine course allows you to discuss a dose reduction with your prescriber, that conversation belongs in their office, not ours.

We want to be honest about expectations. Research suggests that a meaningful subset of patients with chronic phantom limb pain experience clinically important reductions with IV ketamine, but not everyone responds, and durability typically requires either a multi-infusion induction series or periodic boosters. The optimal protocol is still being defined in the pain literature. We will tell you what we know, what we do not, and what a reasonable trial looks like for your situation.